New drug shows promise in preventing SMA symptoms in babies

NCT ID NCT03779334

First seen Dec 11, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This study tests an oral medicine called risdiplam in infants up to 6 weeks old who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal is to see if early treatment helps them reach motor milestones like sitting without support. 26 infants took part, and the study measures how many can sit independently and avoid severe breathing problems or death.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCULAR ATROPHY, SPINAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chr de La Citadelle

    Liège, 4000, Belgium

  • Hospital das Clinicas - FMUSP_X

    São Paulo, São Paulo, 05403-000, Brazil

  • Kaohsiung Medical University Chung-Ho Hospital

    Kaohsiung City, 807, Taiwan

  • Nemours Children's Hospital

    Orlando, Florida, 32837, United States

  • Russian Children Neuromuscular Center of Veltischev

    Moscow, Moscow Oblast, 125412, Russia

  • Sydney Children's Hospital

    Randwick, New South Wales, 2031, Australia

  • Szpital Gdanskiego Uniwersytetu Medycznego

    Gda?sk, 80-952, Poland

Conditions

Explore the condition pages connected to this study.